May 19, 2021 / 02:20PM GMT
Brian Corey Abrahams - RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Good morning, everyone. I'm Brian Abrahams, senior biotech analyst at RBC Capital Markets. Very pleased to have our next presenting company, Gilead, represented by their CFO, Andy Dickinson. Andy, thanks so much for joining us.
Andrew D. Dickinson - Gilead Sciences, Inc. - Executive VP & CFO
Thanks, Brian. I appreciate you having us. Happy to be here.
Questions and Answers:
Brian Corey Abrahams - RBC Capital Markets, Research Division - Senior Biotechnology AnalystAbsolutely. Our pleasure. So maybe just kicking things off, coming off of a seasonally soft first quarter, with COVID exacerbating some of the usual dynamics. How are you -- what's the outlook for the rest of the year? How are you expecting things to progress? And what are you seeing that gives you confidence in a bounce-back?
Andrew D. Dickinson - Gilead Sciences, Inc. - Executive VP & CFO
Yes. That's a